Back

Cardiac reverse remodelling of left heart during vericiguat therapy for high-risk HFrEF

31 August 2026 (08:15 - 08:45)
Organised by: Logo
Congress Presentation Part of: Improving HFrEF therapy further Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Alex Pui-Wai Lee

The Chinese University of Hong Kong, Hong Kong (China)

4 More presentations in this session

Presentation thumbnail
The impact of late-onset reverse remodeling in heart failure with reduced ejection fraction
Doctor H. Ikesugi (Niigata, JP)
Abstract Slides Video
Presentation thumbnail
Impact of higher comorbidity burden on guideline-directed medical therapy in patients with heart failure with reduced ejection fraction
Mr J. Krabbe (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Clinical profile and implementation of guideline-directed medical therapy in specialised heart failure clinics: insights from a multicentre registry
Doctor C. Castro (Talca, CL)
Abstract Slides Video
Presentation thumbnail
Interplay between guideline-directed medical therapy and QRS duration in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure registry
Doctor R. Laborante (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Improving HFrEF therapy further

The Event

Event poster

ESC Congress 2026

31 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Vericiguat and reverse ventricular remodeling in patients with chronic HFrEF and recent heart failure worsening
19 May 2025
thumbnail
Congress Presentation
Left atrial remodeling and diastolic unloading after transcatheter tricuspid repair
28 August 2026
thumbnail
Congress Presentation
Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial
29 August 2026
thumbnail
Congress Presentation
Assessment of venous congestion in HFrEF using VExUS in a cohort of patients treated with Vericiguat
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources